Atlas Private Wealth Advisors Sells 3,707 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Atlas Private Wealth Advisors lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,060 shares of the biopharmaceutical company’s stock after selling 3,707 shares during the quarter. Atlas Private Wealth Advisors’ holdings in Gilead Sciences were worth $455,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Compagnie Lombard Odier SCmA grew its position in Gilead Sciences by 1,706.5% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 560 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 529 shares during the last quarter. Banque Pictet & Cie SA grew its position in Gilead Sciences by 838.6% in the 4th quarter. Banque Pictet & Cie SA now owns 51,621 shares of the biopharmaceutical company’s stock valued at $4,768,000 after acquiring an additional 46,121 shares during the last quarter. AustralianSuper Pty Ltd grew its position in Gilead Sciences by 0.5% in the 4th quarter. AustralianSuper Pty Ltd now owns 1,138,269 shares of the biopharmaceutical company’s stock valued at $105,142,000 after acquiring an additional 5,989 shares during the last quarter. Finally, Roman Butler Fullerton & Co. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $298,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.8%

Shares of NASDAQ:GILD opened at $109.98 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The stock has a market cap of $136.81 billion, a price-to-earnings ratio of 297.24, a PEG ratio of 0.71 and a beta of 0.29. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a 50-day moving average price of $105.67 and a 200-day moving average price of $102.26.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same period last year, the business posted ($1.32) earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,000 shares of company stock valued at $4,630,310 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price for the company. Finally, Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.